Optimizing Bridging Therapies and Post–CAR T Approaches

Video content above is prompted by the following:

1. Dr. O’Dwyer to Dr. Molina: With blinatumomab’s FDA approval in the earlier-line setting in ALL, does this impact how you sequence CAR-T cell therapy for your R/R ALL patients?
2. Dr. O’Dwyer to Dr. Shaughnessy: In real-life day-to-day practice, how often are you utilizing bridging therapy prior to CAR T cells, and what agents are you typically using? What is the role of bridging therapies prior to CAR T cells being infused?
3. Resource link: Park JH et al. Bridging therapies FELIX study. ASH 2024 poster abstract or see Appendix 6
4. Dr. O’Dwyer to Dr. Logan (then open to panelists): What is your consolidation or maintenance treatment approach post CAR T-cell therapy? Can CAR T-cell therapy be a stand-alone therapy?